sever
acut
respiratori
syndrom
viru
sar
coronaviru
instig
region
epidem
canada
sever
asian
countri
newli
identifi
sar
coronaviru
sarscov
transmit
among
human
caus
sever
even
fatal
ill
prevent
vaccin
develop
take
year
complet
advers
reaction
report
veterinari
coronavir
vaccin
antivir
compound
must
relentlessli
pursu
studi
analyz
effect
aurintricarboxyl
acid
ata
sarscov
replic
cell
cultur
found
ata
could
drastic
inhibit
sarscov
replic
viral
product
less
untreat
control
importantli
compar
ifn
b
viral
product
inhibit
compar
untreat
control
addit
compar
ifn
b
ata
approxim
time
potent
ifn
time
interferon
b
highest
concentr
report
literatur
previous
data
indic
ata
consid
candid
antisar
compound
futur
clinic
evalu
new
coronaviru
caus
sever
acut
respiratori
syndrom
sar
identifi
earli
subsequ
name
sar
coronaviru
sarscov
viru
high
tendenc
spread
among
human
mortal
high
complet
understand
pathogenesi
sar
remain
tent
recent
histolog
studi
use
sarscovinfect
patient
lung
sampl
found
diffus
alveolar
damag
may
play
import
role
progress
diseas
even
though
signific
morbid
drop
year
likelihood
evolut
sarscov
human
anim
may
result
reemerg
deadli
viru
coronavirus
envelop
virus
singlestrand
positivesens
rna
genom
approxim
kb
virus
coronaviru
famili
caus
diseas
anim
hcov
sarscov
human
pathogen
among
human
coronavirus
sarscov
one
caus
sever
clinic
consequ
sequenc
comparison
sarscov
genom
sequenc
differ
patient
isol
reveal
high
homolog
yet
sequenc
differ
sarscov
coronavirus
signific
predict
open
read
frame
among
six
link
known
coronaviru
gene
gene
spike
envelop
e
membran
nucleocapsid
n
found
multimer
form
involv
host
cell
signal
transduct
regul
rest
orf
may
encod
gene
unknown
function
antivir
develop
sarscov
vigor
pursu
identif
viru
mix
success
challeng
tan
et
al
screen
antisarscov
clinic
approv
compound
includ
nucleosid
analog
interferon
proteas
inhibitor
revers
transcriptas
inhibitor
neuraminidas
inhibitor
ifn
ribavarin
show
antivir
activ
high
concentr
howev
signific
cytotox
effect
lack
efficaci
also
observ
instanc
two
independ
assay
ribavarin
shown
littl
effect
sarscov
replic
ifn
also
test
antisarscov
activ
howev
moder
inhibit
effect
sarscov
replic
interferon
could
observ
high
concentr
new
drug
develop
glycyrrhizin
report
possess
antisarscov
activ
high
concentr
clearli
continu
search
potent
antisarscov
compound
absolut
necessari
unlik
mani
rna
virus
coronavirus
synthes
multipl
subgenom
mrna
fragment
subgenom
rna
usual
encod
one
protein
uniqu
featur
implic
transcript
coronaviru
rna
import
viru
replic
aurintricarboxyl
acid
ata
shown
inhibit
rna
transcript
vesicular
stomat
viru
also
shown
ata
could
interact
ribosom
protein
vitro
inhibit
protein
synthesi
studi
studi
antivir
effect
ata
sarscov
replic
vero
cell
found
ata
drastic
inhibit
viru
replic
much
compar
untreat
control
littl
toxic
observ
associ
ata
treatment
antivir
select
ata
demonstr
failur
inhibit
adenoviru
replic
importantli
found
ata
much
potent
antisarscov
compound
ifn
b
cell
cultur
viral
plaqu
assay
african
green
monkey
kidney
cell
line
vero
cell
cultur
dulbecco
modifi
eagl
medium
supplement
heatinactiv
fetal
bovin
serum
invitrogen
carlsbad
ca
penicillinstreptomycin
mm
hepe
ph
vero
cell
shown
suscept
sarscov
infect
cell
cultur
maintain
humidifi
co
incub
experi
multipl
infect
moi
aurintricarboxyl
acid
sigma
st
loui
mo
prepar
cultur
media
ad
sampl
serial
dilut
compos
mgml
plaqu
assay
perform
h
postinfect
use
procedur
describ
also
perform
inhibit
analysi
interferon
b
concentr
iuml
western
blot
protein
sampl
vero
cell
extract
fraction
sdspage
invitrogen
carlsbad
ca
transfer
pvdf
membran
use
semidri
protein
transfer
apparatu
biorad
hercul
ca
membran
block
h
skim
milk
tb
buffer
mm
tri
base
mm
nacl
ph
contain
tween
membran
probe
mous
monoclon
antibodi
sarscov
spike
protein
unpublish
data
rabbit
antimous
hrpconjug
antibodi
amersham
bioscienc
piscataway
nj
subsequ
ad
addit
incub
h
result
final
reveal
use
pierc
biotechnolog
supersign
west
femto
maximum
sensit
substrat
rockford
il
realtim
rtpcr
analysi
analysi
perform
prism
realtim
pcr
instrument
perkinelm
wellesley
follow
manufactur
protocol
supernat
sampl
sarscovinfect
vero
cell
collect
viral
rna
extract
use
rneasi
kit
qiagen
valencia
ca
primer
probe
use
rtpcr
follow
probe
caaggtttaccc
forward
accagaatggaggacgcaatg
revers
gctgtgaaccaagacgcagtattat
inhibit
adenoviru
express
egfp
ata
use
compar
studi
inhibit
adenoviru
adeno
x
carri
replic
report
gene
express
egfp
clontech
palo
alto
ca
approxim
mg
adenoviru
x
transfect
cell
use
effecten
qiagen
valencia
ca
follow
addit
serial
dilut
ata
western
blot
analysi
follow
use
antibodi
egfp
clontech
palo
alto
ca
cell
prolifer
assay
xtt
kit
roch
mannheim
germani
use
measur
toxic
ata
briefli
vero
cell
seed
plate
dilut
ata
interferon
ad
cell
incub
h
colorimetr
detect
reagent
xtt
kit
subsequ
ad
cell
result
determin
spectrophotomet
wavelength
nm
test
antisarscov
effect
aurintricarboxyl
acid
ata
wide
rang
concentr
ie
mgml
prepar
minimum
essenti
medium
mem
mm
hepe
ph
fetal
calf
serum
plaqu
assay
use
determin
effect
ata
sarscov
replic
vero
cell
infect
sarscov
plate
serial
dilut
ata
ad
infect
cell
initi
viru
adsorpt
step
twentyfour
hour
postinfect
collect
supernat
aforement
cultur
plaqu
assay
determin
inhibitori
effect
ata
sarscov
replic
shown
fig
comparison
untreat
cell
inhibit
viru
replic
observ
cultur
treat
ata
concentr
mgml
least
inhibit
mg
ml
inhibitori
effect
viral
replic
could
still
observ
mgml
viral
replic
level
time
lower
control
also
compar
inhibitori
effect
ata
sarscov
replic
previous
report
one
ifn
b
end
dilut
ata
ifn
highest
concentr
effect
use
treat
cultur
follow
determin
viru
load
viru
load
h
postinfect
quantifi
realtim
rtpcr
analysi
use
specif
primer
probe
sarscov
nucleocapsid
protein
shown
fig
ata
mgml
inhibit
viru
rna
replic
versu
inhibit
interferon
iuml
interferon
b
iuml
fig
result
suggest
ata
time
potent
interferon
time
potent
interferon
b
antisarscov
activ
analyz
whether
prophylact
effect
ata
pretreat
cell
seri
concentr
ata
interferon
b
h
adsorpt
sarscov
vero
cell
ad
inhibitor
adsorpt
shown
fig
inhibit
effect
ata
interferon
b
sampl
without
pretreat
implic
inhibit
effect
may
take
place
viru
enter
cell
confirm
inhibitori
effect
perform
western
blot
analysi
use
monoclon
antibodi
sarscov
spike
protein
shown
fig
level
protein
significantli
lower
ata
treat
group
untreat
group
concentr
mgl
ata
virtual
block
viral
protein
synthesi
confirm
ata
significantli
inhibit
viral
protein
synthesi
character
specif
antivir
activ
ata
also
test
compound
abil
block
protein
express
adenoviru
replic
replic
defici
adenoviru
type
express
egfp
use
infect
cell
concentr
ata
use
abovement
sarscov
inhibit
experi
ad
adenovirusinfect
cell
western
blot
analysi
subsequ
perform
determin
express
level
egfp
signific
inhibit
observ
atatr
sampl
compar
nonatatr
cell
fig
suggest
inhibit
sarscov
replic
ata
clearli
select
explor
therapeut
potenti
ata
determin
select
index
si
defin
ratio
drug
concentr
caus
cellular
toxic
produc
antivir
effect
end
nonradioisotop
cell
prolifer
analysi
system
xtt
roch
mannheim
germani
use
cc
indic
concentr
caus
cytotox
ec
mean
concentr
inhibitor
inhibit
viru
replic
found
si
ata
versu
ifn
ifn
b
indic
ata
great
potenti
potent
antivir
compound
low
toxic
tabl
low
toxic
cell
cultur
anim
ata
evalu
antivir
activ
immunodefici
viru
type
howev
mechan
involv
abil
inhibit
viru
replic
studi
remain
larg
unknown
also
case
current
studi
sarscov
potenc
ata
sarscov
replic
also
higher
report
chemic
glycyrrhizin
recent
report
nelfinavir
drug
candid
report
two
log
less
inhibit
effect
sarscov
replic
ata
show
three
log
inhibit
effect
biolog
activ
ata
demonstr
quit
complic
includ
inhibit
protein
synthesi
prevent
attach
mrna
ribosom
cellfre
system
suppress
enzym
involv
polynucleotid
metabol
ata
exert
antisarscov
activ
requir
vigor
character
preliminari
result
indic
ata
could
inhibit
sarscov
rna
synthesi
data
shown
vaccin
develop
could
take
year
complet
seriou
advers
reaction
report
coronaviru
vaccin
studi
ie
exacerb
diseas
anim
receiv
vaccin
prior
infect
certain
precaut
propos
develop
sarscov
vaccin
due
potenti
detriment
effect
therefor
search
antisarscov
drug
must
pursu
report
first
time
ata
potent
antisar
compound
low
toxic
tissu
cultur
suggest
could
therapeut
valu
sar
patient
vero
cell
seed
plate
dilut
ata
interferon
b
ad
h
fifti
microlit
reaction
solut
xtt
kit
ad
well
incub
h
activ
cell
prolifer
reflect
read
spectrophotometri
concentr
reagent
inhibit
cell
prolifer
activ
cc
use
compar
concentr
inhibit
sarscov
replic
ec
design
select
index
si
fig
vero
cell
infect
sarscov
treat
serial
dilut
concentr
aurintricarboxyl
acid
cell
transfect
adenoviru
x
construct
express
egfp
h
cell
harvest
subject
sdspage
protein
sampl
subsequ
transfer
pvdf
membran
probe
mous
monoclon
antibodi
sarscov
spike
protein
vero
cell
extract
mous
monoclon
antibodi
egfp
cell
extract
antiaactinin
antibodi
rabbit
antimous
antibodi
conjug
horseradish
peroxidas
use
secondari
antibodi
blot
subsequ
develop
supersign
west
femto
western
blot
kit
pierc
rockford
il
